The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

January 27, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Sirukumab in Phase 3 Trials for RA
Sirukumab is a subcutaneously administered human, anti-interleukin 6 monoclonal antibody. It is currently being investigated in Phase 3 clinical trials for treating patients with moderate to severe active rheumatoid arthritis (RA): SIRROUND-D, SIRROUND-H and SIRROUND-T.1 These three trials are multicenter, randomized and double blind. Additionally, SIRROUND-D and SIRROUND-T are placebo controlled.

You Might Also Like
  • Sirukumab Promising for RA
  • Sirukumab Approval Stalls
  • Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis
Also By This Author
  • NKTR-181 Promising for Chronic Low Back Pain

SIRROUND-D is evaluating patients (n=1,670) with moderate to severe active RA who were nonresponsive to disease-modifying antirheumatic drugs (DMARDs). Its primary efficacy objective will be measured by the reduction of RA signs and symptoms and inhibition of radiographic progression. In SIRROUND-H, the primary study objective is to assess sirukumab efficacy when compared with subcutaneous adalimumab in biologic naive patients (n=559) with moderate to severe active RA who are intolerant to methotrexate (MTX). Patients could be either unresponsive to MTX or inappropriate MTX candidates. Finally, SIRROUND-T is assessing the efficacy of sirukumab as measured by the reduction of RA signs and symptoms in patients with active RA (n=878) who were intolerant to or unresponsive to anti-tumor necrosis factor alpha (TNF-α) therapies. Sirukumab is being administered in 50 mg or 100 mg doses every two or four weeks, depending on the study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Two additional trials include SIRROUND-M in Japanese patients who are unresponsive to sulfasalazine or MTX, and SIRROUND-LTE, the long-term extension study for patients who complete the SIRROUND-T and SIRROUND-D studies.

PsA Treatment Persistence Similar with Biologic Therapy vs. Biologic + DMARD
A recent study evaluated the comparative effectiveness of combination therapy with a TNF-α inhibitor plus a conventional DMARD vs. monotherapy with only a TNF-α inhibitor in treating adult patients with psoriatic arthritis (PsA) who were enrolled in a large U.S. database known as Corrona.2 Patients who had started a TNF-α inhibitor had to have been biologic therapy naive and have had a follow-up appointment ≥90 days after therapy initiation. The time to Clinical Disease Activity Index (CDAI) remission (<2.8) and staying on TNF-α inhibitor therapy (persistence) were the study end points.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Demographics and treatment history were similar for both study groups. A total of 318 patients received combination therapy, and 201 patients received monotherapy. The mean follow-up was 2.1 years, and the mean patient age was 51.6 years. Treatments included MTX (91%), sulfasalazine, leflunomide, etanercept, adalimumab and infliximab. The final analysis included 497 patients for TNF-α persistence and 380 patients for time to remission.

There was no statistically significant difference between monotherapy and combination therapy for TNF-α persistence (31 months vs. 32 months, p=0.73), nor for time to remission (25 months vs. 21 months, p=0.56). Predictors of TNF-α persistence included longer persistence for Hispanic patients and longer duration of PsA. Predictors of shorter persistence included history of MTX use, BI and disease activity.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: combination therapy, DMARD, Psoriatic Arthritis, Rheumatoid Arthritis (RA), sirukumab, TNF inbhibitor

You Might Also Like:
  • Sirukumab Promising for RA
  • Sirukumab Approval Stalls
  • Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)